Duvelisib was the second PI3K inhibitor accredited by the FDA, also determined by a phase III randomized trial.a hundred thirty The efficacy and safety profile on the drug appear similar with Those people of idelalisib, if not marginally beneficial. Regarding different BTK inhibitors, there are several items in progress, but only acalabrutinib is a